Rituximab (Rituxan)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 06:41, 13 May 2012 by Dryang (talk | contribs) (Text replace - "or the prescribing information<ref name="insert"></ref>." to "or the prescribing information.<ref name="insert"></ref>")
Jump to navigation Jump to search

General information

Class/mechanism: Anti-CD20 antibody, chimeric murine/human monoclonal IgG1 kappa, which binds to CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), which is expressed on B-cells. The Fc domain recruits immune effector functions to mediate B-cell lysis. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC).[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

References

  1. ↑ 1.0 1.1 Rituximab (Rituxan) package insert
  2. ↑ Rituximab (Rituxan) package insert (locally hosted backup)
  3. ↑ Rituxan manufacturer's site
  4. ↑ Rituximab (Rituxan) patient drug information (Chemocare)
  5. ↑ Rituximab (Rituxan) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Rituximab_(Rituxan)&oldid=1499"